Vyzulta

Valeant finally wins long-delayed FDA OK for its glaucoma drug, which is more good news for Aerie
Endpoints
Thu, 11/2/17 - 10:19 pm
Valeant Pharmaceuticals
FDA
glaucoma
Aerial BioPharma
Vyzulta
Rhopressa